Nutriband Inc. and AVERSA Technology: Revolutionizing Abuse-Deterrent Buprenorphine Therapy

What is Nutriband Inc. developing with its AVERSA technology?

Nutriband Inc. is developing a novel transdermal delivery system for buprenorphine, utilizing its proprietary AVERSA technology to create abuse-deterrent treatments for opioid use disorder and chronic pain.

Why is the development of AVERSA Buprenorphine significant?

The development is significant as it addresses the urgent need for safer, innovative treatments amidst the opioid epidemic, offering an effective and safer alternative to full opioid agonists.

How does AVERSA technology work?

AVERSA technology is designed to deter abuse of transdermal patches by making it difficult to extract the active drug for misuse, while still delivering the medication effectively for therapeutic use.

Who is involved in the development of AVERSA Buprenorphine?

Nutriband Inc. (NASDAQ: NTRB) is the company behind the development, with its AVERSA pipeline including AVERSA(TM) Fentanyl and AVERSA(TM) Buprenorphine as main candidates.

What are the projected sales for Nutriband’s buprenorphine therapy?

The buprenorphine therapy is projected to reach peak annual sales of $70M – $130M.

Where can I find more information about Nutriband Inc. and its developments?

More information is available in the company’s newsroom at https://ibn.fm/NTRB and through BioMedWire’s coverage at https://www.biomedwire.com/.

What is buprenorphine and what is it used for?

Buprenorphine is a medication approved by the U.S. FDA to treat opioid use disorder and chronic and severe pain, serving as a cornerstone in addiction treatment.

How does AVERSA Buprenorphine compare to other treatments?

AVERSA Buprenorphine offers a safer, abuse-deterrent alternative to traditional opioid treatments, leveraging transdermal delivery to reduce misuse potential while maintaining therapeutic efficacy.

What is the current status of Nutriband’s AVERSA pipeline?

The AVERSA pipeline currently includes two main candidates: AVERSA(TM) Fentanyl and AVERSA(TM) Buprenorphine, with the latter being developed as a novel treatment option.

How can I stay updated on Nutriband Inc.’s progress?

To receive SMS alerts from BioMedWire, text ‘Biotech’ to 888-902-4192 (U.S. Mobile Phones Only) or visit https://www.biomedwire.com/ for the latest news and updates.